Clinical trial

Efficacy and Safety of Bilateral Recto-Intercostal Fascial Plane Block on Perioperative Analgesia in Epigastric Hernia Repair : A Randomized Controlled Trial

NCT06092073

Name

36264PR330/9/23

Description

The aim of this study is to evaluate the efficacy and safety bilateral recto-intercostal fascial plane block (RIFPB) in epigastric hernia.

Trial arms

Trial start

2023-10-21

Estimated PCD

2024-05-01

Trial end

2024-05-01

Status

Recruiting

Treatment

recto-intercostal fascial plane block

Patients will receive bilateral recto-intercostal fascial plane block using 20 mL of bupivacaine 0.25% on each side.

Arms:

RIFPB group

bupivacaine

bupivacaine 0.25%

Arms:

RIFPB group

Size

Primary endpoint

Time to the 1st rescue analgesia

24 hours postoperatively

Eligibility criteria

Inclusion Criteria: * Age 18-65 years. * Both sexes. * American Society of Anesthesiology (ASA) physical status I-II. * Scheduled for elective epigastric hernia repair. Exclusion Criteria: * Obese patients with body mass index (BMI) \>35 kg/m2. * Patients with a large hernia containing bowel. * Patients with local anesthetic allergy.

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}

Updated at

2024-04-03

1 organization

1 product

3 indications

Organization

Product

Indication

Indication

Indication